VIP-Producing Neuroendocrine Tumor

subtype

Identifier: CI-CAN-00004246
Entity page: /cancer/vip-producing-neuroendocrine-tumor ↗
Edges: 14

Neighbours: 7 drugs7 trials
Drawn: 14 of 14 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
VIP-Producing Neuroendocrine Tumor investigated in trials for …INVESTIGATED_IN_TRIALSderived7 of 7
→ investigated in trials for	Bevacizumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	VIP-Producing Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants

VIP-Producing Neuroendocrine Tumor studied in …STUDIED_INderived7 of 7
→ studied in	NCT03583528active not recruiting DOTATOC PET/CT for Imaging NET Patients · condition mapped ALIAS · 7 trials mapped (1 active)	—	—	VIP-Producing Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04915144Phase 2 · withdrawn 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs · condition mapped ALIAS · 7 trials mapped (1 active)	—	—	VIP-Producing Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT01229943Phase 2 · completed Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 7 trials mapped (1 active)	—	—	Pancreatic Vipoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03147768Phase 1 · completed Laser Tissue Welding - Distal Pancreatectomy Sealing Study · condition mapped ONTOLOGY_EXACT · 7 trials mapped (1 active)	—	—	Pancreatic Vipoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02831179Phase 1 · withdrawn Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor · condition mapped ONTOLOGY_EXACT · 7 trials mapped (1 active)	—	—	VIP-Producing Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT00131911Phase 2 · completed Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors · condition mapped PROBABILISTIC · 7 trials mapped (1 active)	—	—	VIP-Producing Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT00075439Phase 2 · completed Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors · condition mapped PROBABILISTIC · 7 trials mapped (1 active)	—	—	VIP-Producing Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains